Pharmacies are yanking cold medicines from shelves. So what are the options now?
The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
Hosted on MSN8h
Reckitt Prescribes More U.S. Production for Drug Supply Chain
Consumer-goods supplier Reckitt Benckiser is looking to respond faster to shifts in demand for over-the-counter ...
Positive Outlook for Crinetics Pharmaceuticals: Strategic Advancements and Strong Financial Position Drive Target Price Increase
Citi analyst David Lebowitz has maintained their bullish stance on CRNX stock, giving a Buy rating yesterday. David Lebowitz’s rating is ...
Acelyrin’s Phase 3 Trial Progress and Uncertainties Lead to Hold Rating
ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...
medtechdive10h
FDA breakthrough device decisions rebound after recent declines
The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...
Advisor1d
A ‘golden age of stock picking’: Belski
Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...
Investors Chronicle2d
The UK stocks boosted and bruised by Donald Trump
Donald Trump returning to the White House triggered new index records in the US, and major UK companies are likely to feel ...
These 2 former stock market darlings are trying my patience! Time to sell?
Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...